Company Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors.
The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism.
In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency.
The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca.
Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
| Country | United Kingdom |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 36 |
| CEO | Denise Scots-Knight |
Contact Details
Address: One Cavendish Place, 4th Floor London, W1G 0QF United Kingdom | |
| Phone | 44 33 3023 7300 |
| Website | mereobiopharma.com |
Stock Details
| Ticker Symbol | MREO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001719714 |
| CUSIP Number | 589492107 |
| ISIN Number | US5894921072 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Denise Vera Scots-Knight Ph.D. | Co-Founder, Chief Executive Officer and Executive Director |
| Charles Edward Sermon | Co-Founder, General Counsel, Business Development and Company Secretary |
| Christine Fox CPA | Chief Financial Officer |
| Dr. John P. Richard M.B.A. | Co-Founder and Chief Business Officer |
| Dr. John A. Lewicki Ph.D. | Chief Scientific Officer |
| Dr. Jackie Parkin | Senior Vice President and Therapeutic Head |
| Alexandra Hughes-Wilson | Chief of Patient Access and Commercial Planning |
| Dr. Suba Krishnan | Senior Vice President of Clinical Development |
| Bo Kara | Senior Vice President and Head of Pharmaceutical Development and CMC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| Apr 8, 2025 | ARS | Filing |
| Apr 8, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 4, 2025 | SCHEDULE 13G | Filing |
| Mar 26, 2025 | 10-K | Annual Report |
| Mar 26, 2025 | 8-K | Current Report |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Jan 23, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |